Colorectal Cancer | Specialty

The colorectal cancer condition center is a comprehensive resource for clinical news and expert insights on colorectal cancer. Read more at OncLive.

Quality of Life Assessment Tools In mCRC

July 23rd 2025

Panelists discuss how they assess quality of life in clinical practice by asking simple questions like “What do you do for fun?” and “How was your week?” rather than relying solely on formal quality of life questionnaires.

Defining Clinically Meaningful Outcomes and Looking Ahead at Future Treatment Options for mCRC

July 23rd 2025

Panelists discuss how they’re excited about future combination therapies, particularly TAS-102 with fruquintinib and novel immunotherapy approaches targeting patients with liver metastases who are typically checkpoint inhibitor refractory.

Dr Gill on Considering Patients’ Concerns Before Treatment Selection in Advanced CRC

July 21st 2025

Sharlene Gill, MD, MPH, MBA, FRCPC, highlights the importance of considering patients’ concerns ahead of treatment decision-making for advanced CRC.

Real-World Analysis Highlights Potential Prognostic Impact of KRAS G12C Mutations in First-Line mCRC

July 21st 2025

Cathy Eng, MD, FACP, FASCO, discusses real-world data on KRAS G12C–mutated mCRC, highlighting its potential prognostic impact in the frontline setting.

Dr Eng on Real-World Outcomes in US Patients With KRAS G12C–Mutated CRC

July 16th 2025

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

The Role of Chemotherapy in Third-Line mCRC Treatment

July 16th 2025

Panelists discuss how they approach rechallenge with chemotherapy, considering it primarily in patients who never truly progressed on oxaliplatin-based therapy or those who might benefit from EGFR antibody reintroduction after a drug holiday.

Fruquintinib in Practice: Nuances of Treatment Management and Future Combination Approaches

July 16th 2025

Panelists discuss how they manage fruquintinib dosing by starting at lower doses (3-4 mg) in patients with poor performance status or frailty, then titrating up as tolerated rather than starting at the full 5 mg dose.

Regorafenib Plus Trifluridine/Tipiracil Shows Early Efficacy in Refractory Metastatic Colorectal Cancer

July 14th 2025

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

Dr Sinicrope on the Efficacy and Safety of mFOLFOX6 Plus Atezolizumab in Stage III dMMR CRC

July 10th 2025

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

Studies Highlight Real-World Gaps in Third-Line mCRC and Evolving Role of Molecular Profiling in GI NETs

July 10th 2025

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Post Hoc Data Highlight Utility of Fruquintinib Across Metastatic Subgroups in Refractory mCRC

July 9th 2025

Rocío García-Carbonero, MD, PhD, discusses findings from a subgroup analysis of FRESCO-2 with fruquintinib in refractory mCRC.

SUNLIGHT Regimen in Third-Line mCRC: Insights on Treatment Management and Practical Nuances

July 9th 2025

Panelists discuss how they modify dosing schedules for TAS-102 (trifluridine/tipiracil), with some preferring every-other-week dosing instead of the standard 2-weeks-on schedule to reduce neutropenia and improve tolerability.

Role of Regorafenib in Third-Line mCRC: Expert Insights on Treatment Strategies and Management Nuances

July 9th 2025

Panelists discuss how clinical trials remain the preferred option in third-line treatment, while acknowledging that regorafenib may benefit from dose reduction strategies and potential combination with immunotherapy in select patients.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC

July 7th 2025

Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment

July 7th 2025

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC

July 5th 2025

Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.

ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC

July 5th 2025

ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.

Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites

July 5th 2025

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.

Real-World Analysis Sheds Light on Fruquintinib Use in Later-Line Metastatic CRC

July 4th 2025

A real-world study in Portugal showed fruquintinib displayed a manageable safety profile and an efficacy trend in refractory colorectal cancer.

Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC

July 4th 2025

Quantitative vessel tortuosity features were able to detect the VEGFR inhibitory mechanism of fruquintinib in metastatic colorectal cancer.

x